Enzyme-based medical products

Enzymatica

Enzymatica is based in Lund, Sweden, and sells medical devices against infectious diseases. The company's first product is ColdZyme® Munspray, which is marketed for cold virus prophylaxis and anti-cold virus therapeutic.

Financials

ENZYMATICA

SEKm 2017 2018 2019
Sales 59 49 56
Sales growth (%) 62,9 -17,9 15
EBITDA -22 -35 -22
EBITDA margin (%) -36,9 -72,5 -39,1
EBIT adj -30 -44 -27
EBIT adj margin (%) -50,8 -91 -48,6
Pretax profit -31 -44 -27
EPS rep -0,34 -0,47 -0,29
EPS growth (%) 50,2 -40,2 39,2
EPS adj -0,34 -0,47 -0,29
DPS 0 0 0
EV/EBITDA (x) -20,7 -7 -12,5
EV/EBIT adj (x) -15 -5,6 -10,1
P/E (x) -14,6 -4,9 -8
P/E adj (x) -14,6 -4,9 -8
EV/sales (x) 7,6 5,1 4,9
FCF yield (%) -5,2 -19,6 -11,5
Dividend yield (%) 0 0 0
Net IB debt/EBITDA 0,2 -1 -2,7

Main shareholders

Enzymatica

Main shareholders Share capital % Voting shares %
Mats K Andersson 13.5 % 13.5 %
Landsbankinn Hf. 10.3 % 10.3 %
Gudmundur Palmasson 10.3 % 10.3 %
Agusta Gudmundsdottir 9.8 % 9.8 %
Håkan Roos 6.9 % 6.9 %
Fibonacci Asset Management AB 6.7 % 6.7 %
Ulf Blom 2.2 % 2.2 %
Jörgen Rexö 2.2 % 2.2 %
Avanza Pension 2.2 % 2.2 %
Nordnet Pensionsförsäkring 1.9 % 1.9 %